Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824583 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL934024 | 1.00 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL19389900 | 0.88 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL193274 | 0.86 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2EPHX2USP2KDM1A | |
| SCHEMBL20811615 | 0.86 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2EPHX2USP2KDM1A | |
| SCHEMBL204377 | 0.86 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2EPHX2USP2KDM1A | |
| SCHEMBL14488570 | 0.85 | NR1H2 (0.42) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL18084469 | 0.85 | NR1H2 (0.42) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL30396554 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 | |
| SCHEMBL9003564 | 0.85 | HSD17B10 (0.46) | HSD17B10SMN1; SMN2EPHX2NPC1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-09-02 | — | — | US | claimed |
| EP-4126821-B1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech Srl (IT) | 2024-05-15 | — | — | EP | claimed |
| US-20230127805-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | ROTTAPHARM BIOTECH S.R.L. (IT) | 2023-04-27 | — | — | US | claimed |
| EP-4126821-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech S.r.l. (IT) | 2023-02-08 | — | — | EP | claimed |
| CN-115515936-A | Process for the preparation of (R) -4- (1- (6- (4- (trifluoromethyl) benzyl) -6-azaspiro [2.5] octane-5-carboxamido) -cyclopropyl) benzoic acid or a salt thereof | 罗达制药生物技术有限责任公司 | 2022-12-23 | — | — | CN | claimed |
| WO-2021191062-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | ROTTAPHARM BIOTECH S.R.L. (IT) | 2021-09-30 | — | — | WO | claimed |
| EP-3885339-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | Rottapharm Biotech S.r.l. (IT) | 2021-09-29 | — | — | EP | claimed |
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-09-02 | — | — | US | disclosed |
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-09-02 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| WO-2015094902-A1 | PHENOXYETHYL CYCLIC AMINE DERIVATIVES AND THEIR ACTIVITY AS EP4 RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| EP-2729445-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm S.p.A. (IT) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004290-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM S.P.A. (IT) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | HSD17B10 2485/4885SMN1; SMN2 1498/4885EPHX2 3141/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885EPHX2 2763/4885 |
| US-12404245-B2 | Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof | BACH1, ADH1C, ADH1A | HSD17B10 2762/4885SMN1; SMN2 940/4885EPHX2 2454/4885 |
| US-20230127805-A1 | PROCESS FOR THE PREPARATION OF (R)-4-(1-(6-(4-(TRIFLUOROMETHYL)BENZYL)-6-AZASPIRO[2.5]OCTANE-5-CARBOXAMIDO)-CYCLOPROPYL) BENZOIC ACID OR A SALT THEREOF | BACH1, ADH1C, ADH1A | HSD17B10 2762/4885SMN1; SMN2 940/4885EPHX2 2454/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | HSD17B10 2805/4885SMN1; SMN2 1278/4885EPHX2 2763/4885 |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | HSD17B10 4150/4885SMN1; SMN2 4790/4885EPHX2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.